UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Sells 51,622 Shares of Charles River Laboratories International, Inc. $CRL

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC trimmed its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 17.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 246,628 shares of the medical research company’s stock after selling 51,622 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 0.50% of Charles River Laboratories International worth $37,122,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of CRL. Goldman Sachs Group Inc. boosted its position in shares of Charles River Laboratories International by 407.0% in the first quarter. Goldman Sachs Group Inc. now owns 997,488 shares of the medical research company’s stock valued at $150,142,000 after acquiring an additional 800,762 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of Charles River Laboratories International by 1,721.1% in the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock valued at $85,811,000 after acquiring an additional 538,792 shares during the period. Royal Bank of Canada boosted its position in shares of Charles River Laboratories International by 304.7% in the first quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company’s stock valued at $94,484,000 after acquiring an additional 472,606 shares during the period. Ameriprise Financial Inc. boosted its position in shares of Charles River Laboratories International by 144.3% in the first quarter. Ameriprise Financial Inc. now owns 544,825 shares of the medical research company’s stock valued at $82,007,000 after acquiring an additional 321,789 shares during the period. Finally, SG Americas Securities LLC lifted its position in Charles River Laboratories International by 16,153.2% in the first quarter. SG Americas Securities LLC now owns 267,202 shares of the medical research company’s stock worth $40,219,000 after purchasing an additional 265,558 shares during the period. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Down 0.3%

Shares of Charles River Laboratories International stock opened at $152.47 on Tuesday. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The stock has a market cap of $7.50 billion, a P/E ratio of -114.64, a P/E/G ratio of 4.89 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The business’s 50 day moving average is $160.76 and its 200-day moving average is $148.51.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $983.76 million. During the same quarter in the prior year, the business posted $2.80 EPS. The business’s revenue was up .6% compared to the same quarter last year. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total transaction of $126,080.00. Following the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts recently commented on the company. JPMorgan Chase & Co. raised their target price on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a “neutral” rating in a research report on Thursday, August 7th. Redburn Atlantic raised Charles River Laboratories International from a “neutral” rating to a “buy” rating and reduced their target price for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Wall Street Zen raised Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Barclays raised their target price on Charles River Laboratories International from $155.00 to $165.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 7th. Finally, Evercore ISI raised their target price on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an “outperform” rating in a research report on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International has an average rating of “Hold” and an average price target of $177.07.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).